MuSK+ Myasthenia Gravis Presenting with Severe Sleep Apnea, Respiratory Dysfunction and Response to Rituximab
DOI:
https://doi.org/10.17161/rrnmf.v2i3.14983Keywords:
Myasthenia gravis, MuSK myasthenia, respiratory, neuromuscular junction, apnea, hypoventilationMetrics
Downloads
References
Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412(1):82-9.
Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(Pt 10):2304-11.
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40.
Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978-80.
Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):327-34.
Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM. Development and validation of the Myasthenia Gravis Impairment Index. Neurology. 2016;87(9):879-86.
Padua L, Tonali P, Aprile I, Caliandro P, Bartoccioni E, Evoli A. Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurol. 2006;13(3):273-6.
Prudlo J, Koenig J, Ermert S, Juhász J. Sleep disordered breathing in medically stable patients with myasthenia gravis. Eur J Neurol. 2007;14(3):321-6.
Katzberg HD, Vajsar J, Vezina K, Qashqari H, Selvadurai S, Chrestian N, et al. Respiratory Dysfunction and Sleep-Disordered Breathing in Children With Myasthenia Gravis. J Child Neurol. 2020;35(9):600-6.
Fernandes Oliveira E, Nacif SR, Alves Pereira N, Fonseca NT, Urbano JJ, Perez EA, et al. Sleep disorders in patients with myasthenia gravis: a systematic review. J Phys Ther Sci. 2015;27(6):2013-8.
Heo SJ, Jun JS, Park D, Lee HW, Kim JS, Park JS. Characteristics of obstructive sleep apnea in myasthenia gravis patients: a single center study. Neurol Sci. 2019;40(4):719-24.
Fromageot C, Lofaso F, Annane D, Falaize L, Lejaille M, Clair B, et al. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil. 2001;82(1):123-8.
Sarwal A, Walker FO, Cartwright MS. Neuromuscular ultrasound for evaluation of the diaphragm. Muscle Nerve. 2013;47(3):319-29.
Nikolić AV, Bačić GG, Daković M, Lavrnić S, Rakočević Stojanović VM, Basta IZ, et al. Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis. Acta Neurol Belg. 2015;115(3):361-5.
Zouvelou V, Rentzos M, Toulas P, Evdokimidis I. MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis. J Neuroimaging. 2011;21(3):303-5.
Niks EH, Kuks JB, Wokke JH, Veldman H, Bakker E, Verschuuren JJ, et al. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve. 2010;42(2):283-8.
Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol. 2009;35(1):103-10.
Cenacchi G, Papa V, Valentina P, Fanin M, Marina F, Pegoraro E, et al. Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies. J Neurol. 2011;258(5):746-52.
Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008;195(1-2):151-6.
Marino M, Basile U, Spagni G, Napodano C, Iorio R, Gulli F, et al. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis. Front Immunol. 2020;11:613.
Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262(5):1115-9.
Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017;56(2):185-96.
Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76-83.
Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12(9):931-5.
Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Monica Alcantara, Clodagh Ryan, Nathan Stall, Robert Jackson, Neha Patel, Hans Katzberg
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.